دورية أكاديمية
Syndrome of liver depression and spleen deficiency is a primary TCM syndrome of response to entecavir + FuZheng HuaYu in patients with HBV-related liver fibrosis.
| العنوان: | Syndrome of liver depression and spleen deficiency is a primary TCM syndrome of response to entecavir + FuZheng HuaYu in patients with HBV-related liver fibrosis. |
|---|---|
| المؤلفون: | Dai YK; Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China., Fan HN; Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China., Zhao ZM; Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.; Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai, 201203, China., Shen L; Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China., Liu CH; Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.; Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai, 201203, China.; Key Laboratory of Liver and Kidney Diseases, Ministry of Education, China. |
| المصدر: | Heliyon [Heliyon] 2023 Nov 13; Vol. 9 (11), pp. e22216. Date of Electronic Publication: 2023 Nov 13 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101672560 Publication Model: eCollection Cited Medium: Print ISSN: 2405-8440 (Print) Linking ISSN: 24058440 NLM ISO Abbreviation: Heliyon Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Elsevier Ltd, [2015]- |
| مستخلص: | Objective: Although clinical studies have found that Chinese patent medicine FuZheng HuaYu tablet/capsule can promote the reversal of HBV-related liver fibrosis, not all sufferers have histopathological responses. This study aims to explore the correlation between traditional Chinese medicine (TCM) syndromes and response to entecavir + FuZheng HuaYu (ETV + FZHY) in patients with HBV-related liver fibrosis. Methods: This a multi-center cross-sectional study. According to the different treatment strategies that sufferers have ever received, a total of 437 cases were included and divided into ETV + FZHY group and ETV + placebo group. And based on the relevant efficacy determination criteria, the two groups were subdivided into efficacy responders and non-responders. Then, TCM clinical questionnaire information of these patients were collected for subsequent analysis to acquire relevant syndrome elements and TCM syndromes. Results: No matter what group was, the first three frequency of TCM pathological position in efficacy responders were as follows: Liver > Spleen > Stomach (TCM concepts). As for the ETV + FZHY group, the first three frequency of pathological nature was ranked as Qi deficiency > Dampness > Heat. Compared with the non-responders, the frequency of Spleen, Stomach, Qi deficiency, Heat, and Qi movement stagnation was significantly increased in the efficacy responders ( P < 0.05). In terms of TCM syndromes, the frequency increase of Syndrome of liver depression and spleen deficiency (LDSD), in the efficacy responders, changed more obviously than the non-responders ( Chi 2 = 6.32, P = 0.0006). Conclusions: TCM syndrome elements of Spleen, Stomach, Qi deficiency, Heat, and Qi movement stagnation were closely associated with efficacy responders with HBV-related liver fibrosis in the ETV + FZHY group. Moreover, LDSD was a primary TCM syndrome in these responders. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2023 Published by Elsevier Ltd.) |
| References: | Cells. 2020 Apr 03;9(4):. (PMID: 32260126) Virulence. 2022 Dec;13(1):258-296. (PMID: 35100095) Evid Based Complement Alternat Med. 2020 May 12;2020:3468791. (PMID: 32454856) Int J Mol Med. 2013 Nov;32(5):1069-76. (PMID: 24026106) J Virol. 2009 Oct;83(19):9652-62. (PMID: 19625407) Evid Based Complement Alternat Med. 2022 Apr 28;2022:5325431. (PMID: 35529927) BMJ Open. 2018 Aug 30;8(8):e020939. (PMID: 30166291) J Integr Med. 2022 Nov;20(6):524-533. (PMID: 36031542) Chin J Integr Med. 2021 Jul;27(7):509-513. (PMID: 32572776) Expert Opin Pharmacother. 2020 Sep;21(13):1637-1650. (PMID: 32543284) BMJ Open. 2015 Jun 03;5(6):e006572. (PMID: 26041487) J Clin Transl Hepatol. 2020 Sep 28;8(3):277-284. (PMID: 33083250) Biomed Pharmacother. 2021 May;137:111367. (PMID: 33588265) J Ethnopharmacol. 2022 Nov 15;298:115599. (PMID: 35932973) Mol Med Rep. 2016 Nov;14(5):4255-4262. (PMID: 27633755) Evid Based Complement Alternat Med. 2022 Jul 15;2022:4494099. (PMID: 35873630) |
| فهرسة مساهمة: | Keywords: Cross-sectional study; Entecavir + FuZheng HuaYu; HBV-related liver fibrosis; Traditional Chinese medicine syndrome characteristics |
| تواريخ الأحداث: | Date Created: 20231204 Latest Revision: 20231205 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10689883 |
| DOI: | 10.1016/j.heliyon.2023.e22216 |
| PMID: | 38045133 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!